-The Hindu Justice Prabha Sridevan’s judgment permitting the production and sale of a generic version of a cancer drug is a victory for patients. It posits the public interest, especially in matters of health care, right at the heart of intellectual property rights in India Monday was a remarkable day for cancer patients in India. To them, the country said — “we care.” I am talking about the astounding decision by Justice...
More »SEARCH RESULT
Total Matching Records found : 76
Bayer plea dismissed, Natco allowed to sell patent cancer drug
-The Business Standard Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India. IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to...
More »Climate change deaths up 5-fold since 1970
-The Times of India Even as one in four deaths worldwide in 2010 was caused by heart disease or stroke the top two killers that have remained constant for the past 40 years human mortality caused by climate change has shown the most dangerous spurt over the last four decades. The Global Burden of Disease Study, 2010, published by the British medical journal, The Lancet, on Thursday shows that there has been...
More »Ganga is now a deadly source of cancer, study says
-The Economic Times KOLKATA: The holy Ganga is a poison river today. It's so full of killer pollutants that those living along its banks in Uttar Pradesh, Bihar and Bengal are more prone to cancer than anywhere else in the country, says a recent study. Conducted by the National Cancer Registry Programme (NCRP) under the Indian Council of Medical Research, the national study throws up shocking findings. The river is thick with...
More »IPAB dismisses Bayer's stay plea in Nexavar case
-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...
More »
